You are here

  • Home
  • Archive
  • Volume 12, Issue 3
  • Review: prokinetics, histamine H2 receptor antagonists, antimuscarinics, and proton pump inhibitors improve global symptoms in non-ulcer dyspepsia

Article Text

Article menu
Download PDFPDF
Therapeutics
Review: prokinetics, histamine H2 receptor antagonists, antimuscarinics, and proton pump inhibitors improve global symptoms in non-ulcer dyspepsia

https://doi.org/10.1136/ebm.12.3.79

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Moayyedi P, Soo S, Deeks J, et al. Pharmacological interventions for non-ulcer dyspepsia. Cochrane Database Syst Rev 2006;(4):CD001960.
    OpenUrlPubMed

    
 
 Q In patients with non-ulcer dyspepsia (NUD), do antacids, histamine H2 receptor antagonists (H2RAs), proton pump inhibitors (PPIs), prokinetics (PROK), mucosal protecting agents (MPAs), and antimuscarinics improve symptoms?

    Clinical impact ratings GP/FP/Primary care ★★★★★★☆ Gastroenterology ★★★★★★★ Internal medicine ★★★★★★☆

    METHODS

    Embedded ImageData sources:

    Medline (1966 to January 2006), CINAHL (1982 to January 2006), EMBASE/Excerpta Medica (1988 to January 2006), Cochrane Central Register of Controlled Trials (Cochrane Library, Issue 4, 2005), SIGLE, bibliographies of relevant studies, experts in the field, and pharmaceutical companies.

    Embedded ImageStudy selection and assessment:

    randomised controlled trials (RCTs) that compared antacids, H2RAs, PPIs, PROK, MPAs, or antimuscarinics with placebo or other drugs in patients with symptoms …

    View Full Text

    Footnotes

    • For correspondence: Professor P Moayyedi, McMaster University, Hamilton, Ontario, Canada. moayyep{at}mcmaster.ca

    • Sources of funding: UK NHS Health Technology Assessment Programme; Medical Research Council; NHS Research and Development Programme.